As Green Cross and SK will not launch tetravalent influenza vaccines, GSK is having the best time
As tetravalent influenza vaccines of Green Cross and SK Chemicals will not be launched in the 2015-2016 season, the domestic tetravalent influenza vaccine market is going to be taken over by GSK.
GSK is willing to reform the Korean influenza vaccine market using the monopolistic circumstance of ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
